| abstract |
REFERS TO COMPOUNDS DERIVED FROM 2- (1H-INDAZOL-6-ILAMINE) -BENZAMIDE, WHERE THEY ARE PREFERRED: N-CYCLOPROPYL-2- {3 - [(E) -2- (4-METHYL-PYRIDIN-2-IL ) -VINYL] -1H-INDAZOL-6-ILAMINO} -BENZAMIDE, N-PROP-2-INYL-2- [3 - ((E) -2-PYRIDIN-2-IL-VINYL) -1H-INDAZOL-6 -YLAMINE] -BENZAMIDE, 2- {3 - [(E) -2- (4,6-DIMETHYL-PYRIDIN-2-IL) -VINYL] -1H-INDAZOL-6-ILAMINO} -N- (4-HYDROXY -BUT-2-INYL) -BENZAMIDE, N- (PROP-2-INYL) -2- {3 - [(E) -2- (2,4-DIMETHYL-PYRIDIN-2-IL) -VINYL] -1H -INDAZOL-6-ILAMINO} -BENZAMIDE, N-PROP-2-INYL-2- [3 - ((E) -2-PYRIDN-2-IL-VINYL) -1H-INDAZOL-6-ILAMINO] -BENZAMIDE, AMONG OTHERS. THESE COMPOUNDS MODULATE AND / OR INHIBIT THE ACTIVITY OF KINASES ASSOCIATED WITH VEGF-R, FGF-R, CDK COMPLEXES, CHK1, LCK, TEK, FAK AND / OR PHOSPHORYLASAKINASE. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION CONTAINING IT AND A PROCEDURE FOR USE. THESE COMPOUNDS ARE USEFUL TO TREAT OPHTHALMIC DISEASES SUCH AS AGE-RELATED MACULAR DEGENERATION, CHOROIDAL NEOVASCULARIZATION, RETINOPATHY, RETINITIS, MACULAR EDEMA. THEY ARE ALSO USEFUL TO TREAT DISEASES MEDIATED BY PROTEINKINASE ACTIVITY ASSOCIATED WITH TUMOR GROWTH, CELL PROLIFERATION OR ANGIOGENESIS |